BiospaceHealth
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Vericel Corporation announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on September 15, 2026. A webcast of the presentation will be available on the company's website.

Automatically summarised by AI from Biospace
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) – Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. A webcast of the presentation will be available on the Investor Relations section of the company's website.
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to offer a portfolio of cell therapies and specialty biologics. The Company currently markets three products in the United States, including MACI® and Epicel®, and holds an exclusive license for North American rights to NexoBrid®.
Epicel®, MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.
Health · Biospace · Published 21:09 · 08 Sept 2026
Read the original ↗
